Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis (CONCERTO)
Idoven 1903 S.L.
2,000 participants
May 27, 2025
OBSERVATIONAL
Conditions
Summary
CONCERTO is a retrospective, observational, multicentric and single-arm study to perform an external validation of the cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, to detect Transthyretin cardiac amyloidosis (ATTR-CA). Thus, this study will assess Willem™ ability to distinguish between truly diagnosed ATTR-CA patients and confirmed non-ATTR-CA patients from ECG data.
Eligibility
Inclusion Criteria2
- Subjects ≥ 18 years old
- Subjects with 12-leads ECG records with a 10 seconds minimum length on digital format
Exclusion Criteria1
- Patients with paced rhythm on the ECG.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06978660